Good Afternoon Market Enthusiast,

Brace yourself, because MAIA Biotechnology (NYSE American: MAIA) is making waves in the biotech world with jaw-dropping advancements in cancer treatment. 🚨

🔬 This isn’t just another company—it’s changing the game!

(6)

🔥 Major Growth on the Horizon

The name to know: THIO, MAIA’s first-in-class telomere-targeting therapy, is taking non-small cell lung cancer (NSCLC) head-on. (5)

And it’s not just showing promise—it’s delivering results that are turning heads across the industry and regulatory agencies alike.

💡 What’s Happening Right Now: 

📜 USAN Council Approval: Just yesterday, the United States Adopted Names (USAN) Council approved Ateganosine as the official nonproprietary name for THIO, marking a major step toward commercialization! 🏆 (1)

🏥 Phase 3 is ON! MAIA is launching a Phase 3 pivotal trial, evaluating THIO in combination with a checkpoint inhibitor vs. chemotherapy for advanced NSCLC patients. (2)

🌍 Expanding Clinical Reach: MAIA expanded its THIO-101 Phase 2 trial, further validating the treatment's efficacy and safety in tackling late-stage cancers. (3)

🧪 The Science That’s Changing the Game

MAIA isn’t just developing treatments—it’s revolutionizing how cancer is fought.

And now, MAIA just dropped a bombshell study that could reshape cancer treatment forever: 

📊 BREAKING: MAIA’s Novel THIO Dimer Shows Unmatched Potency in Overcoming Cancer Resistance! (8)

A newly published peer-reviewed study in Naunyn-Schmiedeberg's Archives of Pharmacology reveals that MAIA’s next-generation THIO dimer is a powerful inhibitor of GSTP1, a key enzyme driving cancer progression and drug resistance. (8)

This discovery could unlock new, more effective ways to enhance standard treatments and outsmart chemotherapy resistance.

Why this matters: (6)(8)
 

• THIO dimer is a dual-action weapon—it doesn’t just attack cancer cells but also prevents them from adapting and resisting treatment.
• Stronger, more effective cancer therapy means higher patient survival rates and fewer treatment failures.
• 80+ THIO-like compounds are in development, opening the door for even bigger breakthroughs in cancer treatment.
   

CEO Dr. Vlad Vitoc put it best: "Our first peer-reviewed paper in this prestigious journal showcases the unique potential of our second-generation THIO program. We are at the forefront of a paradigm shift in oncology." (8)

🎉 Proven Clinical Success

THIO doesn’t just attack tumors—it reprograms the immune system to keep cancer from coming back! 🏥

Why everyone is watching:

• 💀 85% Disease Control Rate (DCR) in NSCLC patients—outperforming conventional treatments! (6)
• 🧪 Orphan Drug Designations for HCC, SCLC, and glioblastoma, reinforcing THIO’s impact across multiple aggressive cancers. (6)
• 💉 Rare Pediatric Disease Designation for high-grade gliomas in children—expanding its lifesaving reach! (6)

👉 Powerful Partnerships and Strategic Expansion

MAIA is not doing this alone—they’re joining forces with industry giants to take their treatment further and faster: (3)(5)(6)(8)

• Collaboration with BeiGene: Combining THIO with tislelizumab in three Phase 2 pivotal trials for HCC, SCLC, and colorectal cancer (CRC).
• Regulatory Acceleration: With MAIA pushing for fast-track FDA approvals, THIO is on a clear path to market entry.
• 100% Complete Response Rate in CRC trials, with NO RECURRENCE after reintroducing more cancer cells. (That’s unheard of!)
   

💪 Strong Backing and Intellectual Property Leadership

The biotech world has taken notice, and MAIA isn’t slowing down:

🌳 $1.43 Million Raised through a non-brokered private placement, reinforcing confidence in their mission. (4)

🔒 Patent Powerhouse: With 5 issued patents and 29 pending, MAIA is protecting its industry-leading innovations. (6)

🌍 The Market is Ready for MAIA’s Expansion

MAIA is at the center of multi-billion-dollar markets that are growing FAST: (2)(3)(6)

• Hepatocellular carcinoma (HCC) 🏥: $780M in 2023, projected to hit $1.5B by 2034
• Small cell lung cancer (SCLC) 🔬: $6.5B market in 2024, expected to expand at 12.3% CAGR through 2034
• Colorectal cancer (CRC) ⚕️: On track to grow from $9.26B in 2018 to $26.49B by 2032

🚨 The Takeaway: MAIA is Just Getting Started

MAIA isn’t just another biotech company—it’s a revolution in the making!

With cutting-edge science, regulatory wins, strategic partnerships, and a rapidly expanding clinical pipeline, MAIA is on a trajectory that’s impossible to ignore.

If you’re following biotech innovation with some serious potential, you NEED to be watching MAIA Biotechnology (NYSE American: MAIA). 🔬🔥

We’ll be keeping a close eye on what’s next as MAIA continues to push boundaries and advance its life-changing therapies!

To your success,

Max Masters

Co-founder, Market Tips Newsletter

Sources:
1. https://finance.yahoo.com/news/maia-biotechnology-receives-usan-council-150000860.html

2. Shttps://finance.yahoo.com/news/maia-biotechnology-initiate-phase-3-135100127.html

3. https://finance.yahoo.com/news/maia-biotechnology-announces-design-expansion-134700870.html

4. https://finance.yahoo.com/news/maia-biotechnology-announces-non-brokered-213000009.html

5. https://finance.yahoo.com/news/maia-biotechnology-announces-private-placement-204400048.html

6. https://d1io3yog0oux5.cloudfront.net/_e28b2621e798ebe03c7d570b55000e6d/maiabiotech/db/2216/[…]/2025-02-04+MAIA+Biotechnology+-+Presentation+Deck.pdf

7. https://finance.yahoo.com/quote/MAIA/history/
8. https://finance.yahoo.com/news/maia-biotechnology-announces-publication-peer-132000569.html 

Paid Promotion. Momentum Media LLC has been hired for a period beginning on 03/20/2025 and ending on 03/20/2025 (the “Campaign”) to publicly disseminate information about MAIA Biotechnology, Inc. (MAIA:US). Momentum Media LLC expects to be compensated $5,000.00 and are owed an additional $0 for the Campaign. To date, we have been paid 34,600.00. Please read Momentum Media LLC’s complete disclaimer at https://markettips.net/disclaimer/ which includes important information. Emojis, graphics and/or images used herein have no specific or implied meaning, and are used for artistic purposes only. Nothing contained herein is financial advice. Momentum Media LLC is not an analyst, st.o.ck broker, financial adviser or st.o.ck picker nor is it qualified to act in the capacity of any of the foregoing. Information herein is a paid advertisement and should not be relied upon as accurate or complete.